N2-(3-(2-(2H-1,2,3-Triazol-2-Yl)Propan-2-Yl)-1-Cyclopropyl-1H-Pyrazol-5-Yl)-N4-Ethyl-5-(Trifluoromethyl)Pyrimidine-2,4-Diamine

2 trials

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

0 Recruiting

2 Completed trials

2 Sponsors

7 Countries

Phase II

Phase II: 2

Indications tested

Parkinson's disease 1

Sponsors using this IMP

Biogen Idec Research Limited 1 Denali Therapeutics Inc. 1

All trials

2 total

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson’s Disease (LRRK2-PD) Ended

2024-513384-15-00 Phase II 2 countries Denali Therapeutics Inc.
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants … Ended

2023-505645-12-00 Phase II 7 countries Biogen Idec Research Limited

Showing 1–2 of 2 trials

← All drugs A–Z